Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05577728 · ClinicalTrials.gov registry record
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 2,316
- Enrollment target
NCT05577728: Completed study, sponsored by Brigham and Women's Hospital.
NCT05577728 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 2,316 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05577728 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 2,316 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Number of subjects
Interventions
- DRUG New use of semaglutide injection
- DRUG New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,316 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-10-31 |
What the finished NCT05577728 record still lists
NCT05577728 is an observational study that tracks outcomes without assigning an intervention. Its 2,316 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which New use of semaglutide injection is the first listed.
NCT05577728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05577728 about?
NCT05577728 is a clinical study titled "Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05577728?
This trial is currently completed. The enrollment target is 2,316 participants. The study started on 2021-07-01. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT05577728?
The interventions under investigation include: New use of semaglutide injection (DRUG), New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) (DRUG).
Who is sponsoring clinical trial NCT05577728?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI